Loading
A phase 3 trial of Atezolizumab, Carboplatin, Etoposide in small-cell lung cancer, run by SystImmune Inc., now recruiting.
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) is a phase 3 interventional study registered as NCT07625644 by SystImmune Inc., with 550 participants planned, started 2026-08-04 and due to reach its primary completion in 2030-01. Interventions recorded: BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin. Conditions listed: Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SystImmune / Sichuan Biokin, Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer.
Shares Lurbinectedin, Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab.
Shares SystImmune / Sichuan Biokin, Extensive-stage small-cell lung cancer, Etoposide, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Etoposide, Carboplatin, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/